These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10953602)

  • 1. [Homocysteine and atherosclerosis. The controlled clinical trials phase that people have been waiting for so long. Can multivitamins reduce coronary disease?].
    López Ridaura R
    Rev Invest Clin; 2000; 52(3):223-6. PubMed ID: 10953602
    [No Abstract]   [Full Text] [Related]  

  • 2. [Homocysteine as a coronary risk factor].
    Derbeneva SA; Pogozheva AV
    Vopr Pitan; 2003; 72(5):43-8. PubMed ID: 14619617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine-lowering trials for prevention of heart disease and stroke.
    Clarke R
    Semin Vasc Med; 2005 May; 5(2):215-22. PubMed ID: 16047274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteine. The association with atherosclerotic vascular disease in older persons.
    Aronow WS
    Geriatrics; 2003 Sep; 58(9):22-4, 27-8. PubMed ID: 14518174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine and coronary heart disease.
    Clarke R; Lewington S
    Semin Vasc Med; 2002 Nov; 2(4):391-9. PubMed ID: 16222629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [For coronary disease patients risky].
    Göller V
    MMW Fortschr Med; 2005 Oct; 147(42):14. PubMed ID: 16281777
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).
    Shenoy KT; Lena KB; Sali N; Syam S; Shenoy ST; Rajadhyaksha VD; Pai GP; Shaikh AA;
    Curr Med Res Opin; 2006 Apr; 22(4):641-8. PubMed ID: 16684424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine--an atherogenic and a thrombogenic factor?
    Ubbink JB
    Nutr Rev; 1995 Nov; 53(11):323-5. PubMed ID: 8643214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AHA symposium/epidemiology meeting: Atherosclerosis. Discussion: Why measure atherosclerosis?
    Kuller LH
    Circulation; 1993 Mar; 87(3 Suppl):II34-7. PubMed ID: 8443921
    [No Abstract]   [Full Text] [Related]  

  • 11. Reducing coronary artery disease by decreasing homocysteine levels.
    Coffey M; Crowder GK; Cheek DJ
    Crit Care Nurse; 2003 Feb; 23(1):25-30. PubMed ID: 12640957
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there any relationship between lipids and vitamin B levels in persons with elevated risk of atherosclerosis?
    Wasilewska A; Narkiewicz M; Rutkowski B; Łysiak-Szydłowska W
    Med Sci Monit; 2003 Mar; 9(3):CR147-51. PubMed ID: 12640345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine and stroke prevention: have the trials settled the issue?
    Spence JD
    Int J Stroke; 2006 Nov; 1(4):242-4. PubMed ID: 18706027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine and occlusive arterial disease.
    O'Grady H; Kelly C; Bouchier-Hayes D; Leahy A
    Br J Surg; 2002 Jul; 89(7):838-44. PubMed ID: 12081732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine-lowering vitamins and cardiovascular mortality: are they really effective?
    Celik T; Iyisoy A; Yuksel UC; Isik E
    Int J Cardiol; 2008 Aug; 128(3):432-3. PubMed ID: 17689750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors].
    Parhofer KG
    MMW Fortschr Med; 2001 Jan; 143(4):22-4. PubMed ID: 11219276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Homocysteine and cerebrovascular disease].
    Sepúlveda-Sánchez JM; Matía-Francés R; Martínez-Salio A; González-de la Aleja-Tejera J; Rodríguez-Peña Marín M; Porta-Etessam J
    Rev Neurol; 2004 Feb 16-29; 38(4):347-58. PubMed ID: 14997460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is plasma homocysteine a modifiable risk factor for stroke?
    Hankey GJ
    Nat Clin Pract Neurol; 2006 Jan; 2(1):26-33. PubMed ID: 16932518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine and cardiovascular risk in patients with diabetes mellitus.
    Yeromenko Y; Lavie L; Levy Y
    Nutr Metab Cardiovasc Dis; 2001 Apr; 11(2):108-16. PubMed ID: 11434188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease.
    Taute BM; Taute R; Heins S; Behrmann C; Podhaisky H
    Int Angiol; 2004 Mar; 23(1):35-40. PubMed ID: 15156128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.